Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
2.160
+0.100 (4.85%)
At close: Jul 30, 2025, 4:00 PM
2.170
+0.010 (0.46%)
After-hours: Jul 30, 2025, 5:03 PM EDT
Company Description
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.
The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
Country | United States |
Founded | 2021 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
CEO | Leonard Mazur |
Contact Details
Address: 11 Commerce Drive, First Floor Cranford, New Jersey 07016 United States | |
Phone | (908) 967-6677 |
Stock Details
Ticker Symbol | CTOR |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0001851484 |
ISIN Number | US17331Y1091 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Leonard L. Mazur | Chairman, Chief Executive Officer and President |
Myron Z. Holubiak | Executive Vice Chairman and Secretary |
Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
Jaime Bartushak | Chief Financial Officer and Treasurer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 25, 2025 | SCHEDULE 13D/A | Filing |
Jul 18, 2025 | 8-K | Current Report |
Jul 17, 2025 | 424B4 | Prospectus |
Jul 16, 2025 | EFFECT | Notice of Effectiveness |
Jul 14, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jul 14, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Jun 27, 2025 | 8-K | Current Report |
Jun 17, 2025 | 8-K | Current Report |
May 14, 2025 | 10-Q | Quarterly Report |
May 14, 2025 | 8-K | Current Report |